Cited by 101Breast Cancer Treatment StudiesBreast Lesions and CarcinomasEndometrial and Cervical Cancer Treatments

Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy

Open access
Olivotto, Ivo A., Lesperance, Mary L., Truong, Pauline T., Nichol, Alan, Berrang, Tanya, Tyldesley, Scott, Germain, François, Speers, Caroline +4 more·2009·Journal of Clinical Oncology

Abstract

Purpose: To determine the interval from breast-conserving surgery (BCS) to radiation therapy (RT) that affects local control or survival. Patients and Methods: The 10-year Kaplan-Meier (KM) local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), and breast cancer–specific survival (BCSS) were computed for 6,428 women who had T1 to 2, N0 to 1, M0 breast cancer that was diagnosed in British Columbia between 1989 and 2003, and who were treated with BCS and RT without chemotherapy. Intervals from BCS to RT were grouped by weeks as follows: ≤ 4 (n = 83), greater than 4 to 8 (n = 2,288; reference group); greater than 8 to 12 (n = 2,606); greater than 12 to 16 (n = 961); greater than 16 to 20 (n = 358); and greater than 20 weeks (n = 132). Cox proportional hazards models and matching were used to control for confounding variables. Results: The median follow-up time was 7.5 years. The 10-year KM outcomes were as follows: LRFS, 95.4%; DRFS, 90.5%; and BCSS, 92.5%. Compared with the greater than 4 to 8 weeks group, hazard ratios (HR) were not significantly different for any outcome among patients who were treated up to 20 weeks after BCS. However, LRFS (hazard ratio [HR], 2.00; P = .15), DRFS (HR, 1.86; P = .02) and BCSS (HR, 2.15; P = .009) were inferior for women with BCS-to-RT intervals greater than 20 weeks compared with those greater than 4 to 8 weeks. The matched analysis yielded similar results. Conclusion: Outcomes were statistically similar for BCS-to-RT intervals up to 20 weeks, but they were inferior for intervals beyond 20 weeks. Time can be reasonably allowed for the breast to heal and for patients to consider treatment options, but RT should start within 20 weeks of BCS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.18.1891

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. O'Reilly S, Olivotto IA: Adjuvant systemic therapy for women with operable breast cancer: Experience in British Columbia, Canada. J Irish Coll Phys Surg 27:177-181, 1998
  2. Lawless JF: Statistical Models and Meth- ods for Lifetime Data (ed 2). Hoboken, NJ, Wiley, 2003

Cited by

Sorted by citations

Authors
Olivotto, I. A., Lesperance, M. L., Truong, P. T., Nichol, A., Berrang, T., Tyldesley, S., Germain, F., Speers, C., Wai, E., Holloway, C., Kwan, W., & Kennecke, H.
Affiliations
BC Cancer Agency (CA)
Venue
Journal of Clinical Oncology
Published
2009-01-01
Volume
27
Issue
1
Pages
16-23
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2130090226
Cited by
101
References
24
Citations by year
2026: 5 · 2025: 1 · 2024: 2 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 22 · 2019: 1 · 2018: 6 · 2017: 5 · 2016: 5 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 7
FWCI
1.71
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
American Society of Clinical Oncology
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
breast-conserving surgery, radiotherapy, early breast cancer, local recurrence-free survival, distant recurrence-free survival, breast cancer-specific survival, timing of radiotherapy, local control, survival outcomes, matched analysis
MeSH terms
Adult, Aged, Aged, 80 and over, Breast Neoplasms, Combined Modality Therapy, Female, Humans, Middle Aged, Neoplasm Staging, Time Factors, Mastectomy, Segmental

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review